Clinical trials: JIA
Juvenile Idiopathic Arthritis
Sleep Shared-Management Intervention for Children With Juvenile Idiopathic Arthritis
Sleep deficiency is a public health concern in children with a chronic illness such as Juvenile Idiopathic Arthritis (JIA) because it is often overlooked in clinical care, attributed to the underlying chronic illness, and…
- Trial name
- SLEEPSMART (NCT04066205)
- Testing
- SLEEPSAMRT
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Washington
Juvenile Idiopathic Arthritis
Safety and Effectiveness of Rilonacept for Treating Systemic Juvenile Idiopathic Arthritis in Children and Young Adults
Systemic juvenile idiopathic arthritis (SJIA) is a type of arthritis that typically occurs before 16 years of age. SJIA usually involves heat, pain, swelling, and stiffness in the body's joints.
- Trial name
- NCT00534495
- Testing
- Rilonacept
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Montefiore Medical Center
Enthesitis Related Arthritis (ERA)
A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis
The purpose of this study is to evaluate the efficacy and safety of adalimumab given subcutaneously every other week (eow) as compared to placebo in pediatric subjects with Enthesitis Related Arthritis (ERA).
- Trial name
- NCT01166282
- Testing
- adalimumab
- Volunteers
- 46 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Juvenile Psoriatic Arthritis, Enthesitis-related Arthritis
Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA)
This was a double-blind, placebo-controlled, event-driven randomized withdrawal study to investigate the efficacy and safety of secukinumab treatment in the Juvenile Idiopathic Arthritis (JIA) categories of Juvenile Psoriatic…
- Trial name
- NCT03031782
- Testing
- secukinumab
- Where
- 31 sites in United States, Belgium and 8 more
- Volunteers
- 86 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Juvenile Idiopathic Arthritis, Hereditary Periodic Fevers
A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies
The objective of this extension protocol is to collect safety data (serious and non-serious adverse events) and to provide continuous canakinumab to patients in France who completed study CACZ885G2301E1(NCT00891046), CACZ885G2306…
- Trial name
- NCT02334748
- Testing
- canakinumab
- Where
- 3 sites in France
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Juvenile Rheumatoid Arthritis
Safety, Efficacy, and Pharmacokinetics of Adalimumab in Japanese Children With Juvenile Rheumatoid Arthritis
To evaluate efficacy, safety and pharmacokinetics of adalimumab in Japanese children with Polyarticular Juvenile Rheumatoid Arthritis
- Trial name
- NCT00690573
- Testing
- Adalimumab
- Where
- 12 sites in Japan
- Volunteers
- 25 people
- Sponsor
- Abbott
Juvenile Chronic Polyarthritis, Juvenile Idiopathic Arthritis
Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis
The purpose of this study is to compare two aggressive drug regimens for children with poly-juvenile idiopathic arthritis (JIA) and extended oligo JIA.
- Conditions
- Juvenile Chronic Polyarthritis, Juvenile Idiopathic Arthritis, Juvenile Rheumatoid Arthritis
- Trial name
- NCT00443430
- Testing
- methotrexate, methotrexate - etanercept - prednisolone arm
- Where
- 15 sites in United States
- Volunteers
- 85 people
- Sponsor
- Seattle Children's Hospital
Juvenile Idiopathic Arthritis
A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab)
PART1 Participants in Part 1 (Run-in-Phase) of study will receive tocilizumab (TCZ) (RoActemra/Actemra) 12 milligrams per kilogram (mg/kg) or 8 mg/kg intravenously (IV) every 2 weeks (Q2W) for up to 24 weeks.
- Trial name
- NCT01734382
- Testing
- Tocilizumab
- Where
- 19 sites in United States, Argentina and 8 more
- Volunteers
- 35 people
- Sponsor
- Hoffmann-La Roche
Juvenile Rheumatoid Arthritis
Etanercept Plus Methotrexate Versus Methotrexate Alone in Children With Polyarticular Course Juvenile Rheumatoid Arthritis
The primary objective of this study was to determine the efficacy of etanercept plus methotrexate vs methotrexate alone in pediatric patients with active polyarticular course juvenile rheumatoid arthritis (JRA).
- Trial name
- NCT03781375
- Testing
- Etanercept, Methotrexate
- Volunteers
- 25 people
- Sponsor
- Amgen
Systemic Juvenile Idiopathic Arthritis
Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA
This was a phase III study designed to provide efficacy and safety data for canakinumab administered for at least 48 weeks as subcutaneous (s.c.) injection every 4 weeks (q4wk) in Japanese patients with Systemic Juvenile…
- Trial name
- NCT02396212
- Testing
- Canakinumab
- Where
- 7 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Novartis Pharmaceuticals
Juvenile Idiopathic Arthritis (JIA)
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
A 6-month study of the safety of VIMOVO in adolescents aged 12 to 16 years with JIA.
- Trial name
- NCT01544114
- Testing
- VIMOVO 250/20, VIMOVO 375/20, VIMOVO 500/20
- Where
- 17 sites in United States
- Volunteers
- 46 people
- Sponsor
- Amgen
Juvenile Idiopathic Arthritis
Internet Self-Management Program With Telephone Support for Adolescents With Arthritis
This study will evaluate the feasibility of "Teens Taking Charge: Managing Arthritis On-line" intervention that will help adolescents with arthritis to better manage their disease and improve their health-related quality of life…
- Trial name
- NCT01011179
- Testing
- Teens Taking Charge, Self-Management
- Where
- 4 sites in Canada
- Volunteers
- 46 people
- Sponsor
- The Hospital for Sick Children
Arthritis
Safety and Efficacy of Gardasil in Females With Juvenile Idiopathic Arthritis (JIA)/Seronegative Arthritis
The purpose of this research study is to see if patients with juvenile idiopathic arthritis or seronegative arthritis (and related conditions) mount protective immune responses to the human papillomavirus (HPV) vaccine called…
- Trial name
- CHASE (NCT00573651)
- Testing
- Blood Draws for Serum Titers
- Where
- 4 sites in United States
- Volunteers
- 43 people
- Sponsor
- University Hospitals Cleveland Medical Center
Juvenile Idiopathic Arthritis
Active Juvenile Idiopathic Arthritis (JIA) Compassionate Use
The main objective of this study is to evaluate the safety of adalimumab in patients 2 to < 4 years of age or ≥ 4 years of age weighing < 15 kg, with moderately to severely active polyarticular juvenile idiopathic arthritis (JIA)…
- Trial name
- NCT00775437
- Testing
- Adalimumab
- Volunteers
- 32 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Polyarticular-course Juvenile Idiopathic Arthritis (JIA)
Pediatric Arthritis Study of Certolizumab Pegol
A Multicenter, Open-label Study to Assess the Pharmacokinetics, Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Polyarticular-course Juvenile Idiopathic Arthritis (JIA).
- Trial name
- PASCAL (NCT01550003)
- Testing
- Certolizumab Pegol (CZP)
- Where
- 36 sites in United States, Argentina and 5 more
- Volunteers
- 193 people
- Sponsor
- UCB BIOSCIENCES GmbH
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE)
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
This is a randomized, multi-site, adaptive, open-label clinical trial comparing the immune response to different additional doses of COVID-19 vaccine in participants with autoimmune disease requiring IS medications.
- Conditions
- Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS)
- Trial name
- NCT05000216
- Testing
- Moderna mRNA-1273, BNT162b2, Ad26.COV2.S
- Where
- 29 sites in United States
- Volunteers
- 258 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Juvenile Idiopathic Arthritis
Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis
The primary objective of this Phase 4, multi-center, open-label study is to evaluate the safety and tolerability of DUEXIS in Juvenile Idiopathic Arthritis (JIA) patients aged 10 years to 16 years, 11 months, treated up to 24…
- Trial name
- NCT01563185
- Testing
- 800 mg ibuprofen/26.6 mg famotidine
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Amgen
Juvenile Idiopahtic Arthritis
Extension Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis
This is a 8-year extension study in pediatric subjects who have been diagnosed with one of 3 subtypes of Juvenile Idiopathic Arthritis (JIA) [extended oligoarticular JIA, enthestitis related arthritis (ERA), or psoriatic…
- Trial name
- CLIPPER2 (NCT01421069)
- Testing
- etanercept
- Where
- 35 sites in Australia, Belgium and 17 more
- Volunteers
- 109 people
- Sponsor
- Pfizer
Juvenile Rheumatoid Arthritis
BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis
The primary purpose of the clinical research study is to assess the safety of treating children and juvenile subjects with BMS-188667 (Abatacept).
- Trial name
- NCT00095173
- Testing
- Abatacept
- Where
- 36 sites in United States, Austria and 9 more
- Volunteers
- 214 people
- Sponsor
- Bristol-Myers Squibb
Juvenile Idiopathic Arthritis
Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis
Evaluate long-term safety and tolerability of tofacitinib in patients with JIA, who have previously participated in tofacitinib JIA studies.
- Trial name
- NCT01500551
- Testing
- Tofacitinib
- Where
- 104 sites in United States, Argentina and 17 more
- Volunteers
- 302 people
- Sponsor
- Pfizer